Herein, we highlight the potential of BTLA as a therapeutic target in CLL, unveiling that BTLA expression is highly upregulated in patients with CLL, whereas HVEM expression is downregulated. The gene discussed is BTLA; the disease is B-cell chronic lymphocytic leukemia.